CBLL — CeriBell, Inc.

CeriBell, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $24.8 million, a 34% increase from $18.5 million in Q4 2024.
• Full Year 2025 Revenue: $89.1 million, representing a 36% growth over 2024.
• Gross Margins: 87% for Q4 and 88% for the full year, slightly down in Q4 due to increased tariffs on products from China.
• Operating Expenses: $36.2 million in Q4 (up 24% year-over-year) and $136.7 million for the full year (up 42% year-over-year).
• Net Loss: $13.5 million in Q4 ($0.36 per share) compared to a loss of $12.6 million in Q4 2024. Full year net loss was $53.4 million ($1.46 per share).
• Active Accounts: 647 by year-end, with 32 new accounts added in Q4.

2. Strategic Updates and Business Highlights

• Market Expansion: Total addressable market (TAM) increased from $2 billion to over $3.5 billion, driven by FDA clearance for pediatric and neonatal seizure detection products.
• Commercial Infrastructure: Expanded from 35 to approximately 55 territories, with a strong backlog of accounts interested in adopting CeriBell's technology.
• New Product Launches: Anticipated full commercial launch of pediatric and neonate products in Q2 2026, along with a pilot for delirium monitoring.
• Regulatory Milestones: Received FDA 510(k) clearance for delirium detection and Breakthrough Device designation for LVO stroke monitoring.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $111 million and $115 million, representing a growth of 25% to 29% over 2025.
• Sales Strategy: Focus on accelerating account acquisition and utilization, particularly in existing accounts, with a goal to deepen penetration in the core seizure market.
• Long-Term Goals: Aiming for cash flow breakeven with ongoing investments in R&D and commercial infrastructure to support growth.

4. Bad News, Challenges, or Points of Concern

• Operating Losses: Continued net losses, with a significant increase in operating expenses attributed to investments in commercial infrastructure and legal expenses related to ongoing litigation.
• Margin Pressures: Anticipated gross margins in the mid-80% range due to tariff impacts and increased costs associated with product launches.
• Sales Cycle: The expected sales cycle for new products may delay revenue impact, particularly for neonate products, which could take several months to ramp up.
• Litigation Risks: Ongoing patent infringement litigation with Natus could lead to increased legal costs and operational distractions.

5. Notable Q&A Insights

• Growth Levers: Management emphasized the importance of both account acquisition and same-store growth, with expectations for increased account adds in 2026 compared to 2025.
• Delirium Commercial Plan: Discussions are ongoing with existing accounts for the commercial pilot, focusing on real-world validation and workflow optimization.
• VA Expansion: Current projections include the impact of previously committed expansions within the VA system, but further growth from this segment is not yet incorporated into guidance.
• Pricing Strategy: CeriBell intends to maintain pricing discipline despite potential macroeconomic pressures, with evaluations on a case-by-case basis.

Overall, CeriBell, Inc. demonstrated strong growth in 2025, with significant strategic initiatives set to enhance its market position in 2026, though challenges remain in terms of profitability and operational execution amidst ongoing litigation.